Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of impact of renal impairment and lymphodepletion on outcomes after CAR T in RRMM provides signal supporting feasibility/safety of bendamustine-based LD and highlight prognostic relevance of renal function w/ cilta-cel.”
Title:Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Authors: Nora Grieb, Thomas Wiemers, Patrick Born, David Fandrei, Luise Fischer, Maximilian Ferle, Stefan Franke, Johannes Keller, Song Yau Wang, Madlen Jentzsch, Carmen Herling, Klaus H. Metzeler, Marco Herling, Simone Heyn, Thomas Neumuth, Uwe Platzbecker, Vladan Vučinić, Georg-Nikolaus Franke, Maximilian Merz
You can read the Full Article in Transplantation and Cellular Therapy.
You can find other articles featuring Robert Orlowski on OncoDaily.
